Welcome!

News Feed Item

Antibacterial Drugs: World Industry and Market Prospects 2014-2024

LONDON, March 11, 2014 /PRNewswire/ --

Antibacterials - new analysis showing business trends, R&D, and revenue forecasts

What is the future of medicines treating bacterial infections? For those drugs you get new sales predictions, also exploring research and development. Those treatments hold high potentials. There you assess results, progress, therapies, and opportunities.

Knowledge facilitates success. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. There you stay ahead in data on microbial diseases, finding commercial prospects to benefit your influence.

Read on to explore antibiotics for human healthcare, seeing how high sales can go.

Forecasts to 2024 and other analyses explain and predict that antimicrobials market

Why miss data you need? Why struggle to find it, or fall behind? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find recent results, growth rates, market shares, and discussions.

Also you see the potential of research and development. That study gives 126 tables, 102 charts, and interviews with three companies.

There you assess the future of antibacterials, hearing how patients, doctors, and pharma companies can benefit. You stay ahead, then, finding where money lies, assessing the most lucrative selling prospects.

And the following sections show how that new investigation helps your research, analyses and decisions. See there how you could benefit your authority and save time, staying ahead.

Sales predictions for the world antibiotics market and submarkets

What is that biomedical industry's potential? What are the secrets of its progress? Discover in our report overall world revenue to 2024 for those bacteria-treating agents.

Also find individual revenue predictions to 2024 for six therapeutic submarkets at world level:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other treatments for bacterial infections.

There you explore prospects from 2014, hearing where you could profit from novel agents and generic drugs (generics). Investigate competition, developments, and rising sales.

That study also predicts and discusses leading medicines' sales potentials

To see an exec summary of this report please email Sara Peerun on [email protected] .

Revenue predictions for leading and expected products

How will individual drugs perform to 2024 at world level? Our study forecasts revenues of 43 products - marketed agents and drugs awaiting launch.

You assess top products, including these:
• Zyvox
• Augmentin
• Cubicin
• Generic amoxicillin
• Avelox.

There you find medicines and years with highest predicted sales. Also you examine competitors and get an understanding of recent challenges, trends, and outlooks.

For that overall market, the report also shows geographical revenue predictions.

National markets - what are the demands for antibacterial therapies?

In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2014 to 2024. See where and how.

Our analyses show you individual revenue forecasts to 2024 for a regional block and 12 national markets:
United States (US)
• European Union (EU) - also with separate forecasts for France, Germany, the UK, Italy, and Spain (EU5 countries)
Japan
South Korea
• The BRIC nations - Brazil, Russia, India, and China.

For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for fighting bacterial infections, also assessing the expected financial gains.

And what events change that industry? Our work shows you, discussing trends, challenges and opportunities.

Market forces and issues - what affects antibiotic developers, producers and sellers?

The report shows you issues and events affecting that industry and market from 2014, including these:
• Antibacterial drug consumption statistics at national level
• Incidences of urinary tract, skin, and respiratory tract infections from bacteria
• Generic competition for leading brands - effects of patent expiries
• Prescription control to reduce bacterial resistance, including that of methicillin-resistant S. aureus (MRSA)
• Encouraging antibiotic drug discovery and development - push and pull incentives, inc. public-private collaborations.

And you explore these influences, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other new drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies.

Discover what the future holds. There you explore political, economic, social, and technological questions. See, too, how R&D lets companies benefit patients.

There you find what stimulates and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on [email protected]

Analysis of top companies and potential for market growth - what revenue is possible?

From 2014, new treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from bacteria-treating drugs.

So what happens next? Our study predicts that world market will reach $42.75bn in 2018, with further expansion to 2024.

That work also explores activities and potentials of these companies, among others:
• Pfizer
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• Bayer
• Cubist Pharmaceuticals
• Daiichi Sankyo.

R&D in that industry holds strengths, and from 2014 opportunity arises. Patients, payers, and companies will benefit. Discover what is possible.

And you will be able to see how that market can perform, staying ahead in knowledge and benefiting your reputation for commercial insight.

Ways Antibacterial Drugs: World Industry and Market Prospects 2014-2024  helps you

In particular, that new investigation gives you this information:
• Revenues there to 2024 at world level, for 6 submarkets, and 43 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, strategies, R&D, and outlooks for success.

Knowledge found nowhere else, helping your searches, analyses, and planning

Our study gives independent data. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore the commercial possibilities.

With that original research and analysis you are less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort. And also help your plans, decisions, influence, and competing.

The new report shows commercial potentials of medicines for human infective diseases. There you explore trends and R&D, and investigate future sales. So avoid missing out - please order now.

Companies Listed in this report:
Abbott
AbbVie
Achaogen
ACS Dobfar
Actavis
Actelion Pharmaceuticals
Aeras
Affinium Pharmaceuticals
Alcon
Alkem Laboratories
Allied Pharma
AmpliPhi Bioscience
Apotex
APP Pharmaceuticals
Aptalis Pharma
Aquapharm Biodiscovery
Aradigm
Aridis Pharmaceuticals
Arsanis Biosciences
Ascend Therapeutics
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Basilea Pharmaceutica
Bayer
Biomax Biotechnics
Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority (BARDA)
Brazilian National Health Surveillance Agency
Cadila Healthcare
Calixa Therapeutics
Cardeas Pharma
Cellceutix
Cempra Pharmaceuticals
Centers for Disease Control and Prevention (CDC)
Chinese Ministry of Health
Chiron
Cipla
Claris Lifesciences
Clinigen
Cornerstone Therapeutics
Corona Remedies
Critical Therapeutics
Cubist Pharmaceuticals
Curetis
Daiichi Sankyo
Dainippon Sumitomo
Destiny Pharma
Discuva
Dr. Reddy's Laboratories
Duke University
Durata Therapeutics
Eli Lilly
Emcure Pharmaceuticals
Eros Pharma
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Fitch Ratings Agency
Food and Drug Administration (US FDA)
Forest Laboratories
Fraunhofer-Gesellschaft
Furiex Pharmaceuticals
Gate Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Generics
GlycoVaxyn
Guangdong BeiKang
Hetero
Hi Tech Pharma
Hikma Pharmaceuticals
Hospira
Indian Ministry of Health and Family Welfare
Insmed
Intercell
Itochu Chemical Frontier
Janssen Pharmaceutica
Japanese Ministry of Health Labor and Welfare
Johns Hopkins University School of Medicine
Johnson & Johnson
KaloBios
Kenta Biotech
Kuhnil Pharm
Lupin
Macleod Pharmaceuticals
Medicines and Healthcare Products Regulatory Agency
Medicis
MedImmune
Medison Pharma
Medsintez
Meiji Seika Pharma
Melinta Therapeutics
Merck & Co.
MerLion Pharmaceuticals
Microlabs
MicuRx Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW, Japan)
Mpex Pharmaceuticals
Mylan
Nabriva Therapeutics
Nalneva
National Institute for Health and Clinical Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Neiss Labs
Nektar Therapeutics
Nichi-Iko Pharmaceuticals
Nipro Pharma
Novacta Biosystems
Novartis
Novexel
Optimer Pharmaceuticals
Orchid Healthcare
Paratek Pharmaceuticals
Pearl Therapeutics
Pfizer
Phico Therapeutics
Piramal Healthcare,
Plenus Pharmaceuticals
Pliva
Polyphor
Procarta Biosystems
Procter & Gamble
Ranbaxy Labs
Redx Pharma
Roche
Roxane
R-Pharma
RQx Pharmaceutical
Sagent Pharmaceuticals
Sandoz
Sanofi
Sanofi Pasteur
Savara Pharmaceuticals
Sawai Pharmaceutical
Sequella
Shanghai MengKe Pharmaceuticals
Shanghai Zhangjiang Biomedical Industry Venture Capital
Shionogi
Shire
Sidmak Labs
Sistema Nacional de Gerenciamento de Produtos Controlados
Solitaire Pharmacia
Specialised Therapeutics
Sunovion Pharma
TaiGen Biotechnology
Taisho Pharmaceuticals
Taiyo Yakuhin
Takeda
TAP Holdings
Targanta Therapeutics
Tedec-Meiji Farma
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Torrent Pharmaceuticals
Trius Therapeutics
TTY Biopharma
Unichem Laboratories
University of Leicester
University of Michigan
US Department of Health
Valeant Pharmaceuticals
Vansen Pharma
Vicuron
ViroPharma
Warner Chilcott
Watson
Wockhardt
World Health Organization (WHO)
Zhejiang Medicine Company
Zuelig Pharma
Zydus Pharmaceuticals

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel : +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1215/Antibacterial-Drugs-World-Industry-and-Market-Prospects-2014-2024


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
"We want to show that our solution is far less expensive with a much better total cost of ownership so we announced several key features. One is called geo-distributed erasure coding, another is support for KVM and we introduced a new capability called Multi-Part," explained Tim Desai, Senior Product Marketing Manager at Hitachi Data Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I'm here to leverage my secret sauce, which is using outsourced development and the company that I utilize is delaPlex Software and they've basically allowed me to win Fortune 500 companies," noted Justin Witz, CTO of FRA and PlanTools, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We provide IoT solutions. We provide the most compatible solutions for many applications. Our solutions are industry agnostic and also protocol agnostic," explained Richard Han, Head of Sales and Marketing and Engineering at Systena America, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"As we've gone out into the public cloud we've seen that over time we may have lost a few things - we've lost control, we've given up cost to a certain extent, and then security, flexibility," explained Steve Conner, VP of Sales at Cloudistics,in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are an IT services solution provider and we sell software to support those solutions. Our focus and key areas are around security, enterprise monitoring, and continuous delivery optimization," noted John Balsavage, President of A&I Solutions, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Calligo, an innovative cloud service provider offering mid-sized companies the highest levels of data privacy and security, has been named "Bronze Sponsor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Calligo offers unparalleled application performance guarantees, commercial flexibility and a personalised support service from its globally located cloud plat...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
"Peak 10 is a hybrid infrastructure provider across the nation. We are in the thick of things when it comes to hybrid IT," explained Michael Fuhrman, Chief Technology Officer at Peak 10, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We were founded in 2003 and the way we were founded was about good backup and good disaster recovery for our clients, and for the last 20 years we've been pretty consistent with that," noted Marc Malafronte, Territory Manager at StorageCraft, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.